Related Experiment Video
Updated: May 30, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Dentatorubral-pallidoluysian atrophy
1Department of Neurology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan. tsuji@m.u-tokyo.ac.jp
Handbook of Clinical Neurology
|August 11, 2011
Summary
Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare neurodegenerative disease caused by expanded CAG repeats. Mutant protein accumulation in neuronal nuclei, not inclusions, drives DRPLA pathology.
Area of Science:
- Neurogenetics
- Molecular Neurology
- Autosomal Dominant Disorders
Background:
- Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disorder.
- Clinical manifestations include ataxia, choreoathetosis, myoclonus, epilepsy, dementia, and psychiatric symptoms, with significant heterogeneity based on age of onset.
- A key feature is genetic anticipation, particularly with paternal transmission.
Purpose of the Study:
- To investigate the pathological mechanisms underlying Dentatorubral-pallidoluysian atrophy (DRPLA).
- To clarify the role of mutant DRPLA protein accumulation in neuronal nuclei.
Main Methods:
- Immunohistochemical analysis of autopsied tissues from DRPLA patients.
- Examination of mutant DRPLA protein (atrophin-1) localization and accumulation patterns.
Main Results:
- Diffuse accumulation of mutant DRPLA protein (atrophin-1) within neuronal nuclei is the predominant pathological finding.
- Neuronal intranuclear inclusions (NIIs) are not the primary pathological hallmark.
- Pathology affects a broader range of central nervous system regions than previously recognized.
Conclusions:
- Age-dependent and CAG repeat-dependent intranuclear accumulation of mutant DRPLA protein is the essential pathophysiologic mechanism in DRPLA.
- Nuclear dysfunction resulting from mutant protein buildup is central to DRPLA pathogenesis.
Related Concept Videos
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...